Metyrapone compared with placebo for mild autonomous cortisol secretion
Tests metyrapone against placebo in adults with mild autonomous cortisol secretion.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 90 people, planned
- Started
- Oct 2026
- Expected to end
- Dec 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Metyrapone 250 mg Oral Tablets
- Placebo
- Record updated
- 25 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild autonomous cortisol secretion (MACS), where the adrenal glands make slightly too much cortisol on their own. It compares overnight metyrapone with a placebo (dummy pill).
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- MACS with a benign (non-cancer) look on adrenal imaging, such as adrenal adenoma or macronodular or micronodular adrenal hyperplasia. People must also have at least one of: obesity (BMI>30 kg/m2), abnormal blood sugar, abnormal blood fats, high blood pressure, osteopenia, osteoporosis or fragility fractures.
- Earlier treatment
- People cannot join if they now take or plan to take oral glucocorticoids, or opioids >20 MME/day. No injectable glucocorticoid within 6 weeks before Day 1.
- Biomarker or test result
- At least 2 abnormal dexamethasone suppression test results: 1 mg post-dexamethasone cortisol >1.8 mcg/dL or 8 mg post-dexamethasone cortisol >1 mcg/dL. Results from within 24 months before enrolment can be used.
Main reasons for not taking part
- Other treatment for MACS planned within 12 months of joining
- Pregnancy or breastfeeding
- Known allergy to metyrapone
- Uncontrolled illness, such as active infection, heart failure with symptoms, unstable angina or irregular heartbeat
- Suspected false positive dexamethasone test results
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Provide written informed consent
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Age ≥ 18 years
- Diagnosed with MACS i. at least 2 abnormal post-dexamethasone cortisol results1 mg post-dexamethasone cortisol >1.8 mcg/dL or ii. 8 mg post-dexamethasone cortisol >1 mcg/dL b. Historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment
- Adrenal imaging phenotype consistent with benign disease (adrenal adenoma/s, macronodular or micronodular adrenal hyperplasia)
- At least one of the following comorbidities:; obesity (BMI>30 kg/m2); dysglycemia; dyslipidemia; hypertension; osteopenia; osteoporosis; fragility fractures
- Ability to take oral medication and be willing to adhere to the study intervention regimen
- For persons of childbearing potential: : agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of ≤ 5% per year during the treatment period and for 1 month after the last dose of study treatment
- Stable timing for bedtime for at least one week prior to on-site study visits
- History of difficulty providing blood via standard blood draw methods
Who cannot take part
- Planned alternative therapy for MACS within 12 months after joining the study
- Current use of oral exogenous glucocorticoid therapy
- Current use of opioid therapy >20 MME/day
- Planned use of oral exogenous glucocorticoid therapy
- Planned use of opioid therapy >20 MME/day
- Use of injectable glucocorticoid within 6 weeks prior to Day 1
- Investigator's judgement based on history/physical examination that a comorbidity or concomitant medication may impact the hypothalamic-pituitary-adrenal axis or steroid metabolome
- Suspected false positive post-dexamethasone cortisol results due to increased metabolism, poor absorption, or noncompliance with dexamethasone
- Treatment with another investigational drug or other intervention within lower than specific therapy washout period
- Uncontrolled intercurrent illness including, but not limited to:; Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia; Psychiatric illness/social situations that would limit compliance with study requirements
- Known allergic reactions to metyrapone
- Pregnancy or lactation
Where in United States
- Mayo ClinicRochester, United StatesContact: Vanessa Fell, MATaking people
About the trial
What the trial wants to find out
single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.
The 2 groups in the trial
- MetyraponeTreatment being tested
Subjects in the Metyrapone arm will receive the study drug
Treatment: Metyrapone 250 mg Oral Tablets
- PlaceboPlacebo, for comparison
Subjects in the placebo arm will receive a placebo in lieu of study drug
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Metyrapone in Subjects Diagnosed With Mild Autonomous Cortisol Secretion (MACS)
- Plain-language title
- Metyrapone compared with placebo for mild autonomous cortisol secretionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 25 September 2026